Academic Journal
New prospects in the use of Kadcyla® in breast cancer
| العنوان: | New prospects in the use of Kadcyla® in breast cancer |
|---|---|
| المؤلفون: | G. A. Dashyan, V. F. Semiglazov, P. V. Krivorot’ko, R. M. Paltuev, E. E. Topuzov, T. Yu. Semiglazova, E. K. Zhil’tsova, R. V. Donskikh, T. T. Tabagua, V. S. Apollonova |
| المصدر: | Опухоли женской репродуктивной системы, Vol 11, Iss 4, Pp 46-52 (2015) |
| بيانات النشر: | ABV-press, 2015. |
| سنة النشر: | 2015 |
| المجموعة: | LCC:Gynecology and obstetrics |
| مصطلحات موضوعية: | her-2-positve breast cancer, metastatic breast cancer, targeted therapy, trastizumab, t-dm1, transtuzumab emtansine, kadcyla, Gynecology and obstetrics, RG1-991 |
| الوصف: | As is known, the HER-2-expressing biological subtype of breast cancer (BC) is characterized by an aggressive course and has a poorprognosis in the absence of specific treatment. Before the emergence of trastuzumab, 5-year overall survival in patients with the disseminated forms of BC was 20 % (median survival, 16–29 months), out of whom only 2–5 % were long-term survivors. Addition of trastuzumab, a humanized monoclonal antibody that binds selectively to HER-2 receptor on the surface of tumor cells, to first-line chemotherapy for HER-2-positive metastatic BC caused a considerable enhancement of therapeutic efficiency. When trastuzumab is incorporated into chemotherapy for metastatic BC, median progression-free survival and overall survival were 7.4 and 25.1 months (4.6 and 20.3 months without trastuzumab), respectively. Kadcyla® (T-DM1), an antibody-drug conjugate, represents a new approach to treating HER-2-positive metastatic BC. T-DM1 is characterized by the innovative and selective mechanism of action on the HER-2-positive tumor cells. Through this mechanism, T-DM1 leads to a double antitumor effect: a trastuzumab-mediated anti-HER-2 effect and a cytotoxic effect due to the selective transport of the potent antimitotic agent DM1 into the cytoplasm. This mechanism of action enhances the efficiency of antitumor therapy and reduces toxicity. Kadcyla® has been approved in the Russian Federation, as well as by the European Medicines Agency and the United States Food and Drug Administration as monotherapy in HER-2-positive inoperable locally advanced or metastatic BC patients previously treated with taxanes and / or trastuzumab. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | Russian |
| تدمد: | 1994-4098 1999-8627 |
| Relation: | https://ojrs.abvpress.ru/ojrs/article/view/458; https://doaj.org/toc/1994-4098; https://doaj.org/toc/1999-8627 |
| DOI: | 10.17650/1994-4098-2015-11-4-46-52 |
| URL الوصول: | https://doaj.org/article/af3e095f924344fdb4f749e144760fb4 |
| رقم الانضمام: | edsdoj.f3e095f924344fdb4f749e144760fb4 |
| قاعدة البيانات: | Directory of Open Access Journals |
| تدمد: | 19944098 19998627 |
|---|---|
| DOI: | 10.17650/1994-4098-2015-11-4-46-52 |